Hunter Syndrome and Bullʼs Eye Maculopathy

Sadiq Said; Frank Blaser; Bianca Link; Jeanne Martine Gunzinger; James Hanson; Katrin Fasler; Daniel Rudolf Muth; Daniel Barthelmes; Sandrine Zweifel

doi:10.1055/a-2243-4636

Klinische Monatsblätter für Augenheilkunde, Inhaltsverzeichnis

Klin Monbl Augenheilkd 2024; 241(04): 463-467
DOI: 10.1055/a-2243-4636

Der interessante Fall

Hunter Syndrome and Bullʼs Eye Maculopathy

Hunter-Syndrom und Schießscheiben-Makulopathie

Sadiq Said

¹Department of Ophthalmology, University Hospital Zurich, Switzerland

,

Frank Blaser

¹Department of Ophthalmology, University Hospital Zurich, Switzerland

,

Bianca Link

²Division of Metabolism, Connective Tissue Unit, University Childrenʼs Hospital Zurich, Switzerland

,

Jeanne Martine Gunzinger

¹Department of Ophthalmology, University Hospital Zurich, Switzerland

³Department of Ophthalmology, Hunter New England Health, New Lambton, Australia

,

James Hanson

¹Department of Ophthalmology, University Hospital Zurich, Switzerland

,

Katrin Fasler

¹Department of Ophthalmology, University Hospital Zurich, Switzerland

,

Daniel Rudolf Muth

¹Department of Ophthalmology, University Hospital Zurich, Switzerland

⁴Department of Clinical Neuro Science, Karolinska Institute, Stockholm, Sweden

,

Daniel Barthelmes

¹Department of Ophthalmology, University Hospital Zurich, Switzerland

⁵Save Sight Institute, University of Sydney CAR, Glebe, Australia

,

Sandrine Zweifel

¹Department of Ophthalmology, University Hospital Zurich, Switzerland

References
1 Quittot N, Sebastiao M, Bourgault S. Modulation of amyloid assembly by glycosaminoglycans: from mechanism to biological significance. Biochem Cell Biol 2017; 95: 329-337
2 Nagpal R, Goyal RB, Priyadarshini K. et al. Mucopolysaccharidosis: A broad review. Indian J Ophthalmol 2022; 70: 2249-2261
3 DʼAvanzo F, Rigon L, Zanetti A. et al. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. Int J Mol Sci 2020; 21: 1258
4 Lin HY, Chuang CK, Huang YH. et al. Causes of death and clinical characteristics of 34 patients with Mucopolysaccharidosis II in Taiwan from 1995–2012. Orphanet J Rare Dis 2016; 11: 85
5 Fenzl CR, Teramoto K, Moshirfar M. Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses. Clin Ophthalmol 2015; 9: 1633-1644
6 Hoffmann MB, Bach M, Kondo M. et al. ISCEV standard for clinical multifocal electroretinography (mfERG) (2021 update). Doc Ophthalmol 2021; 142: 5-16
7 Robson AG, Frishman LJ, Grigg J. et al. ISCEV Standard for full-field clinical electroretinography (2022 update). Doc Ophthalmol 2022; 144: 165-177
8 Ashworth JL, Biswas S, Wraith E. et al. Mucopolysaccharidoses and the eye. Surv Ophthalmol 2006; 51: 1-17
9 Guillen-Navarro E, Domingo-Jimenez MR, Alcalde-Martin C. et al. Clinical manifestations in female carriers of mucopolysaccharidosis type II: a Spanish cross-sectional study. Orphanet J Rare Dis 2013; 8: 92
10 Ashworth JL, Biswas S, Wraith E. et al. The ocular features of the mucopolysaccharidoses. Eye (Lond) 2006; 20: 553-563
11 Fahnehjelm KT, Tornquist AL, Winiarski J. Ocular axial length and corneal refraction in children with mucopolysaccharidosis (MPS I-Hurler). Acta Ophthalmol 2012; 90: 287-290
12 Tomatsu S, Pitz S, Hampel U. Ophthalmological Findings in Mucopolysaccharidoses. J Clin Med 2019; 8: 1467
13 Wraith JE, Scarpa M, Beck M. et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 2008; 167: 267-277
14 Salvucci IDM, Finzi S, Oyamada MK. et al. Multimodal image analysis of the retina in Hunter syndrome (mucopolysaccharidosis type II): Case report. Ophthalmic Genet 2018; 39: 103-107
15 Kim S, Yoo YJ, Woo SJ. et al. Early Retinal Changes in Hunter Syndrome According to Spectral Domain Optical Coherence Tomography. Korean J Ophthalmol 2016; 30: 151-153
16 Yoon MK, Chen RW, Hedges 3rd TR. et al. High-speed, ultrahigh resolution optical coherence tomography of the retina in Hunter syndrome. Ophthalmic Surg Lasers Imaging 2007; 38: 423-428
17 Kadomoto S, Muraoka Y, Uji A. et al. Human Foveal Cone and Muller Cells Examined by Adaptive Optics Optical Coherence Tomography. Transl Vis Sci Technol 2021; 10: 17
18 Abdulaziz N, Shah AR, McCune WJ. Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. Curr Opin Rheumatol 2018; 30: 249-255
19 Scarpa M, Almassy Z, Beck M. et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 2011; 6: 72
20 Fujimoto J, Swanson E. The Development, Commercialization, and Impact of Optical Coherence Tomography. Invest Ophthalmol Vis Sci 2016; 57: OCT1-OCT13